FDA grants fast track designation to Synageva BioPharma LAL drug
SBC-102, which is under clinical trials, is a recombinant human lysosomal acid lipase enzyme responsible for the breakdown of cholesteryl esters and triglycerides. Synageva R&D CMO and head
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.